TABLE 2.

Inhibition of TNF-α secretion in LPS-stimulated human monocytes treated with different concentrations of telithromycin

Donor	Time (h)	Amt (ng/ml) of TNF-α after treatment with the following concn (μg/ml) of telithromycin (% decreasea):
		0	1	5	10
A	3	1.35 ± 0.036	1.29 ± 0.023	1.20 ± 0.012	1.15 ± 0.012
	6	2.40 ± 0.027	2.43 ± 0.023 (0)	2.05 ± 0.018b (15)	1.63 ± 0.013b (33)
	24	0.67 ± 0.009	0.47 ± 0.010	0.35 ± 0.010	0.31 ± 0.009
B	3	2.11 ± 0.013	1.91 ± 0.015	1.65 ± 0.038	1.33 ± 0.021
	6	2.66 ± 0.034	2.43 ± 0.029 (7)	2.12 ± 0.037b (20)	1.76 ± 0.027b (35)
	24	0.87 ± 0.008	0.91 ± 0.008	0.70 ± 0.010	0.42 ± 0.006
C	3	0.63 ± 0.010	0.55 ± 0.011	0.53 ± 0.008	0.50 ± 0.007
	6	1.22 ± 0.036	1.12 ± 0.046 (7)	1.00 ± 0.032b (21)	0.82 ± 0.013b (36)
	24	0.12 ± 0.006	0.08 ± 0.003	0.06 ± 0.004	0.02 ± 0.003
D	3	4.40 ± 0.030	5.28 ± 0.052 (0)	3.49 ± 0.034b (22)	3.12 ± 0.019b (30)
	6	1.58 ± 0.018	1.41 ± 0.034	1.08 ± 0.046	1.05 ± 0.033
	24	0.83 ± 0.009	0.78 ± 0.006	0.61 ± 0.005	0.38 ± 0.008
E	3	0.77 ± 0.007	0.63 ± 0.005	0.50 ± 0.004	0.48 ± 0.007
	6	1.98 ± 0.042	1.87 ± 0.071 (9)	1.50 ± 0.054b (21)	1.17 ± 0.057b (42)
	24	0.60 ± 0.005	0.53 ± 0.006	0.47 ± 0.008	0.27 ± 0.006
F	3	1.35 ± 0.011	1.50 ± 0.013	1.39 ± 0.013	1.19 ± 0.016
	6	2.95 ± 0.035	2.74 ± 0.019 (8)	2.09 ± 0.012b (31)	1.67 ± 0.012b (45)
	24	1.10 ± 0.008	0.59 ± 0.007	0.41 ± 0.008	0.29 ± 0.002
G	3	0.71 ± 0.008	0.41 ± 0.007	0.29 ± 0.005	0.28 ± 0.004
	6	3.35 ± 0.034	2.85 ± 0.029 (16)	2.11 ± 0.037b (36)	1.42 ± 0.039b (58)
	24	1.49 ± 0.011	1.61 ± 0.009	1.42 ± 0.015	1.01 ± 0.011
H	3	0.86 ± 0.011	0.74 ± 0.009	0.69 ± 0.006	0.65 ± 0.003
	6	1.41 ± 0.052	1.54 ± 0.027 (0)	0.67 ± 0.004b (52)	0.50 ± 0.006b (65)
	24	0.45 ± 0.007	0.31 ± 0.004	0.24 ± 0.003	0.20 ± 0.006

^aPercent decrease from the amount secreted by LPS-stimulated monocytes not treated with telithromycin.

^bP ≤ 0.01.